BR112015024462A2 - composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor da xantina oxidase, e, agente terapêutico ou profilático para uma doença - Google Patents
composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor da xantina oxidase, e, agente terapêutico ou profilático para uma doençaInfo
- Publication number
- BR112015024462A2 BR112015024462A2 BR112015024462A BR112015024462A BR112015024462A2 BR 112015024462 A2 BR112015024462 A2 BR 112015024462A2 BR 112015024462 A BR112015024462 A BR 112015024462A BR 112015024462 A BR112015024462 A BR 112015024462A BR 112015024462 A2 BR112015024462 A2 BR 112015024462A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- compound
- xanthine oxidase
- therapeutic
- pharmaceutically acceptable
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000069 prophylactic effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 title abstract 2
- 108010093894 Xanthine oxidase Proteins 0.000 abstract 2
- 102100033220 Xanthine oxidase Human genes 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 abstract 1
- 208000009911 Urinary Calculi Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000010380 tumor lysis syndrome Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013072788 | 2013-03-29 | ||
| PCT/JP2014/059912 WO2014157740A1 (ja) | 2013-03-29 | 2014-03-28 | ピラゾール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015024462A2 true BR112015024462A2 (pt) | 2017-07-18 |
Family
ID=51624694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015024462A BR112015024462A2 (pt) | 2013-03-29 | 2014-03-28 | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor da xantina oxidase, e, agente terapêutico ou profilático para uma doença |
Country Status (31)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018126349A (ru) | 2015-12-18 | 2020-01-20 | Новартис Аг | Индановые производные и их применение в качестве активаторов растворимой гуанилатциклазы |
| US11344539B2 (en) | 2016-02-19 | 2022-05-31 | National University Corporation Tottori University | Therapeutic or prophylactic drug for dementia |
| EP4516781A1 (en) * | 2022-04-27 | 2025-03-05 | Atom Therapeutics Co., Ltd. | Compound for reducing uric acid |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346094A (en) * | 1980-09-22 | 1982-08-24 | Eli Lilly And Company | 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels |
| US4495195A (en) | 1982-11-01 | 1985-01-22 | Eli Lilly And Company | Xanthine oxidase inhibiting 3(5)-phenyl-substituted-5(3)-pyrazole-carboxylic acid derivatives, compositions, and methods of use |
| ID21775A (id) | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
| JPH10310578A (ja) | 1996-11-13 | 1998-11-24 | Yoshitomi Pharmaceut Ind Ltd | ３−フェニルピラゾール化合物 |
| BR9910578A (pt) * | 1998-04-28 | 2001-01-09 | Novartis Ag | Derivados de piridina substituìda por n-heteroarila e seu uso como herbicidas |
| PT1020454E (pt) * | 1998-06-19 | 2009-12-21 | Teijin Pharma Ltd | Modificações polimórficas do ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazole-carboxílico e processos para a sua preparação |
| WO2005111003A1 (en) | 2004-04-29 | 2005-11-24 | Abbott Laboratories | Amino-tetrazoles analogues and methods of use |
| JP2007043457A (ja) | 2005-08-03 | 2007-02-15 | Masamichi Mochizuki | 携帯電話 |
| JP4849594B2 (ja) | 2005-09-30 | 2012-01-11 | フマキラー株式会社 | 送風式薬剤放散装置 |
| EP1932833B1 (en) * | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| ES2355068T3 (es) * | 2005-10-07 | 2011-03-22 | Astellas Pharma Inc. | Derivado del ácido triarilcarboxílico. |
| CA2643272A1 (en) | 2006-02-24 | 2007-08-30 | Astellas Pharma Inc. | Gent for treating or preventing digestive ulcer |
| CA2644963A1 (en) * | 2006-03-31 | 2007-10-11 | Novartis Ag | Organic compounds |
| JP2008126770A (ja) | 2006-11-17 | 2008-06-05 | Big Tool Co Ltd | 自動車用窓ガラスの取り外し方法 |
| JP5132132B2 (ja) | 2006-11-17 | 2013-01-30 | ヤマハ発動機株式会社 | 船舶用操舵装置及び船舶 |
| WO2008126772A1 (ja) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | 高血圧治療剤 |
| WO2008126770A1 (ja) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体の製造方法 |
| WO2010044403A1 (ja) | 2008-10-15 | 2010-04-22 | キッセイ薬品工業株式会社 | ５員環ヘテロアリール誘導体及びその医薬用途 |
| WO2011011712A1 (en) * | 2009-07-24 | 2011-01-27 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
| EP2464647B1 (en) * | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| JP4939578B2 (ja) | 2009-08-19 | 2012-05-30 | 株式会社沖データ | 現像剤搬送装置、現像剤収容器、及び画像形成装置 |
| TWI423962B (zh) | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
-
2014
- 2014-03-28 NO NO14775913A patent/NO2980085T3/no unknown
- 2014-03-28 CN CN201480018955.8A patent/CN105189476B/zh not_active Expired - Fee Related
- 2014-03-28 SI SI201430658T patent/SI2980085T1/en unknown
- 2014-03-28 ME MEP-2018-105A patent/ME03055B/me unknown
- 2014-03-28 SM SM20180387T patent/SMT201800387T1/it unknown
- 2014-03-28 MY MYPI2015703292A patent/MY176149A/en unknown
- 2014-03-28 LT LTEP14775913.8T patent/LT2980085T/lt unknown
- 2014-03-28 PL PL14775913T patent/PL2980085T3/pl unknown
- 2014-03-28 MX MX2015013333A patent/MX363191B/es unknown
- 2014-03-28 HR HRP20180644TT patent/HRP20180644T1/hr unknown
- 2014-03-28 PT PT147759138T patent/PT2980085T/pt unknown
- 2014-03-28 BR BR112015024462A patent/BR112015024462A2/pt active Search and Examination
- 2014-03-28 DK DK14775913.8T patent/DK2980085T3/en active
- 2014-03-28 ES ES14775913.8T patent/ES2666918T3/es active Active
- 2014-03-28 RU RU2015141274A patent/RU2632884C2/ru active
- 2014-03-28 JP JP2015508836A patent/JP6091603B2/ja not_active Expired - Fee Related
- 2014-03-28 AU AU2014244855A patent/AU2014244855B2/en not_active Ceased
- 2014-03-28 SG SG11201507939XA patent/SG11201507939XA/en unknown
- 2014-03-28 RS RS20180453A patent/RS57154B1/sr unknown
- 2014-03-28 EP EP14775913.8A patent/EP2980085B1/en active Active
- 2014-03-28 KR KR1020157026553A patent/KR20150138212A/ko not_active Abandoned
- 2014-03-28 WO PCT/JP2014/059912 patent/WO2014157740A1/ja active Application Filing
- 2014-03-28 CA CA2904142A patent/CA2904142A1/en not_active Abandoned
- 2014-03-28 NZ NZ712680A patent/NZ712680A/en not_active IP Right Cessation
- 2014-03-28 US US14/774,517 patent/US9617240B2/en not_active Expired - Fee Related
- 2014-03-28 HU HUE14775913A patent/HUE037813T2/hu unknown
-
2015
- 2015-09-21 IL IL241772A patent/IL241772B/en active IP Right Grant
- 2015-09-28 SA SA515361238A patent/SA515361238B1/ar unknown
- 2015-09-28 ZA ZA2015/07146A patent/ZA201507146B/en unknown
- 2015-09-29 PH PH12015502264A patent/PH12015502264B1/en unknown
-
2018
- 2018-04-30 CY CY181100450T patent/CY1120672T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015018033A8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112015011497A2 (pt) | composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença | |
| BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| MY161001A (en) | Tetrahydrocarboline Derivative | |
| EA201290451A1 (ru) | Способ лечения фибрилляции предсердий | |
| WO2011106729A3 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| Shu et al. | Low-molecular-weight fucoidan inhibits the viability and invasiveness and triggers apoptosis in IL-1β-treated human rheumatoid arthritis fibroblast synoviocytes | |
| BR112015017525A2 (pt) | peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado | |
| WO2014126944A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
| BR112015022092A2 (pt) | derivado de di-hidropiridazina-3,5-diona | |
| BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? | |
| WO2015095097A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
| BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
| JP2016535780A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP2987786A4 (en) | AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE | |
| BR112015024462A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor da xantina oxidase, e, agente terapêutico ou profilático para uma doença | |
| MX2017000634A (es) | Inhibidores del canal de potasio medularmente externo renal. | |
| BR112012021445B8 (pt) | formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade | |
| BR112012015170A2 (pt) | "derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dor." | |
| BR112013000042A2 (pt) | composto para inibição da fosfodiesterase tipo 5 e método de preparação do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |